MED
Earnings season, but make it a stress test
Medifast is next up to the plate on May 4th, and this one has all the vibes of a company trying to explain why the treadmill is still not being used. The maker of the Optavia weight-loss program is expected to post fiscal Q1 2026 results, with revenue seen sliding 36.3% and earnings landing at a 55-cent loss per share.
The problem isn’t subtle
That’s not exactly a “things are back on track” forecast. The core issue remains the same old duo:
- a pressured coach base
- soft demand for the company’s offerings
In plain English: if fewer coaches are selling and fewer customers are biting, the whole growth machine sputters. That matters because Medifast is still in the awkward phase where investors care less about flashy branding and more about whether the business can stop leaking momentum.
What investors should watch
The headline numbers will matter, sure, but the real tea leaves are in management’s commentary. You’ll want to hear whether:
- the coach network is stabilizing
- customer demand is improving at all
- margins are holding up despite lower sales
- the company is giving any sign that the slide is slowing
If management sounds optimistic but the numbers are still ugly, that’s usually code for “we’re still in the turnaround slide deck.” If they can point to even tiny signs of stabilization, though, the stock could get a little breathing room.
Big picture: this is less a celebration lap and more a check-in to see whether Medifast is still stuck in the weeds or starting to climb out.